175 related articles for article (PubMed ID: 38527762)
1. Oncolytic varicella-zoster virus engineered with ORF8 deletion and armed with drug-controllable interleukin-12.
Jiang H; Nace R; Carrasco TF; Zhang L; Whye Peng K; Russell SJ
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38527762
[TBL] [Abstract][Full Text] [Related]
2. The attenuated genotype of varicella-zoster virus includes an ORF0 transitional stop codon mutation.
Peters GA; Tyler SD; Carpenter JE; Jackson W; Mori Y; Arvin AM; Grose C
J Virol; 2012 Oct; 86(19):10695-703. PubMed ID: 22837206
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model.
Lee YS; Kim JH; Choi KJ; Choi IK; Kim H; Cho S; Cho BC; Yun CO
Clin Cancer Res; 2006 Oct; 12(19):5859-68. PubMed ID: 17020994
[TBL] [Abstract][Full Text] [Related]
4. Genetic analysis of varicella-zoster virus ORF0 to ORF4 by use of a novel luciferase bacterial artificial chromosome system.
Zhang Z; Rowe J; Wang W; Sommer M; Arvin A; Moffat J; Zhu H
J Virol; 2007 Sep; 81(17):9024-33. PubMed ID: 17581997
[TBL] [Abstract][Full Text] [Related]
5. The requirement of varicella zoster virus glycoprotein E (gE) for viral replication and effects of glycoprotein I on gE in melanoma cells.
Mo C; Lee J; Sommer M; Grose C; Arvin AM
Virology; 2002 Dec; 304(2):176-86. PubMed ID: 12504560
[TBL] [Abstract][Full Text] [Related]
6. Analysis of varicella zoster virus attenuation by evaluation of chimeric parent Oka/vaccine Oka recombinant viruses in skin xenografts in the SCIDhu mouse model.
Zerboni L; Hinchliffe S; Sommer MH; Ito H; Besser J; Stamatis S; Cheng J; Distefano D; Kraiouchkine N; Shaw A; Arvin AM
Virology; 2005 Feb; 332(1):337-46. PubMed ID: 15661165
[TBL] [Abstract][Full Text] [Related]
7. Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse.
Moffat JF; Zerboni L; Kinchington PR; Grose C; Kaneshima H; Arvin AM
J Virol; 1998 Feb; 72(2):965-74. PubMed ID: 9444989
[TBL] [Abstract][Full Text] [Related]
8. Vaccine Development for Varicella-Zoster Virus.
Sadaoka T; Mori Y
Adv Exp Med Biol; 2018; 1045():123-142. PubMed ID: 29896666
[TBL] [Abstract][Full Text] [Related]
9. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
[TBL] [Abstract][Full Text] [Related]
10. Genome-wide mutagenesis reveals that ORF7 is a novel VZV skin-tropic factor.
Zhang Z; Selariu A; Warden C; Huang G; Huang Y; Zaccheus O; Cheng T; Xia N; Zhu H
PLoS Pathog; 2010 Jul; 6(7):e1000971. PubMed ID: 20617166
[TBL] [Abstract][Full Text] [Related]
11. Dysregulated Glycoprotein B-Mediated Cell-Cell Fusion Disrupts Varicella-Zoster Virus and Host Gene Transcription during Infection.
Oliver SL; Yang E; Arvin AM
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795423
[TBL] [Abstract][Full Text] [Related]
12. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.
Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF
J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208
[TBL] [Abstract][Full Text] [Related]
13. Varicella zoster virus infection of malignant glioma cell cultures: a new candidate for oncolytic virotherapy?
Leske H; Haase R; Restle F; Schichor C; Albrecht V; Vizoso Pinto MG; Tonn JC; Baiker A; Thon N
Anticancer Res; 2012 Apr; 32(4):1137-44. PubMed ID: 22493342
[TBL] [Abstract][Full Text] [Related]
14. A Novel Human Skin Tissue Model To Study Varicella-Zoster Virus and Human Cytomegalovirus.
Lloyd MG; Smith NA; Tighe M; Travis KL; Liu D; Upadhyaya PK; Kinchington PR; Chan GC; Moffat JF
J Virol; 2020 Oct; 94(22):. PubMed ID: 32878893
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
Deng L; Fan J; Guo M; Huang B
Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
[TBL] [Abstract][Full Text] [Related]
16. Intratumor injection of oncolytic adenovirus expressing HSP70 prolonged survival in melanoma B16 bearing mice by enhanced immune response.
Ren Z; Ye X; Fang C; Lu Q; Zhao Y; Liu F; Liang M; Hu F; Chen HZ
Cancer Biol Ther; 2008 Feb; 7(2):191-95. PubMed ID: 18073525
[TBL] [Abstract][Full Text] [Related]
17. Recombination of Globally Circulating Varicella-Zoster Virus.
Norberg P; Depledge DP; Kundu S; Atkinson C; Brown J; Haque T; Hussaini Y; MacMahon E; Molyneaux P; Papaevangelou V; Sengupta N; Koay ES; Tang JW; Underhill GS; Grahn A; Studahl M; Breuer J; Bergström T
J Virol; 2015 Jul; 89(14):7133-46. PubMed ID: 25926648
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the Whole-Genome Sequence of an Oka Varicella Vaccine from China with Other Oka Vaccine Strains Reveals Sites Putatively Critical for Vaccine Efficacy.
Wu Q; Rivailler P; Xu S; Xu W
J Virol; 2019 May; 93(9):. PubMed ID: 30728261
[TBL] [Abstract][Full Text] [Related]
19. [Construction of a new oncolytic virus oHSV2hGM-CSF and its anti-tumor effects].
Shi GL; Zhuang XF; Han XP; Li J; Zhang Y; Zhang SR; Liu BL
Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):89-95. PubMed ID: 22780924
[TBL] [Abstract][Full Text] [Related]
20. Mutational analysis of open reading frames 62 and 71, encoding the varicella-zoster virus immediate-early transactivating protein, IE62, and effects on replication in vitro and in skin xenografts in the SCID-hu mouse in vivo.
Sato B; Ito H; Hinchliffe S; Sommer MH; Zerboni L; Arvin AM
J Virol; 2003 May; 77(10):5607-20. PubMed ID: 12719553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
